title: Leverage nonclinical development of bispecifics by translational science.
abstract: Bispecific antibody constructs (Bispecifics, bsAbs) may have greater functionality compared to established monoclonal antibodies because they bind to 2 different targets or, potentially, to 2 epitopes on the same target (dual targeting). This may result in enhanced binding avidity with preferential binding to cells that express both targets or binding to targets on different cells. However, development of these next-generation biologics, including new formats, creates unique challenges due to their increased complexity. Here we review aspects of bsAbs preclinical development programs that may increase the success rates of bsAbs in clinical development.
authors.affiliation: Bayer Pharma AG, 13342 Berlin, Germany. Electronic address: andreas.baumann@bayer.com.
authors.forename: Andreas
authors.initials: A
authors.lastname: Baumann
authors.affiliation: AbbVie Germany GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Fischmann
authors.affiliation: AbbVie Germany GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany.
authors.forename: Guenter
authors.initials: G
authors.lastname: Blaich
authors.affiliation: Amgen Research (Munich) GmbH, Staffelseestr. 2, 81477 Munich, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Friedrich
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000493:pharmacokinetics / Q000494:pharmacology / Q000633:toxicity; D006801:Humans; D057170:Translational Research, Biomedical
chemical_list: D018033:Antibodies, Bispecific